SecBot SecBot

CURX

Curanex Pharmaceuticals Inc
Nasdaq· Pharmaceutical Preparations· Inc. NV· CIK 0002025942 Biotech & Drug Discovery
$4.76 +0.16 (+3.58%)
Oct 27 4:00 PM ET · prev $4.60
Market cap
$7.3M
Nano cap
1 year
−70.2%
from $16.00 · Oct 27
30 days
−5.4%
from $5.03
52-week range
$3.66–16.00
−70% from high · low Jul 27
Avg volume 20D
18.2K
Oct 7 spike 102.0K
Short interest
🔒 Subscribers only
New fund stakes
0
Q2 2026 13F · 0 exits
Filing reports
6
analyzed by SecBot
SecBot read MIXED 2 reports · 90 days
Balance 0 bearish · 0 bullish · 2 neutral oldest → newest, height = score
Avg score ·High conf. 2/2
Strongest NEUTRAL Curanex Pharmaceuticals disclosed two newly filed securities class actions related to its August 2025 IPO…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • InstitutionsMIXED

    Q2 2026: 1 added (0 new), 3 trimmed or exited.

  • TrendUPTREND

    1% above its 50-day average.

Who's buying

13F· Q2 2026
0
new positions
0
exits
FundMoveSharesValue
CITADEL ADVISORS LLCADD95,258$25.3K
GEODE CAPITAL MANAGEMENT, LLCTRIM38,288$10.2K
CITIGROUP INCTRIM8,957$2.4K
UBS Group AGNEAR_EXIT1,506$400.00
GEODE CAPITAL MANAGEMENT, LLCDOUBLED111,130$56.8K
UBS Group AGTRIM7,995$4.1K
JANE STREET GROUP, LLCTRIM24,990$8.3K
UBS Group AGNEAR_EXIT12,991$4.3K

Quarterly 13F filings are due 45 days after each quarter ends.

Earnings setup

Estimates
PeriodEPS est.Range30D rev.Revenue
Current Q———$0.00
Next Q———$0.00
Current FY———$0.00
Next FY———$0.00
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Recent
Sep 3, 2026
Listing
Listing Status: CURX — Normal (was Deficient)
Curanex Pharmaceuticals Inc - Common Stock | Nasdaq Financial Status Indicator D → N
Aug 20, 2026
Trading halt
Halt Resumed: CURX — trading resumed after T3 (News and Resumption Times)
Halted 2026-08-19T23:50:00.000Z | Resumed 2026-08-20T13:00:00.000Z
Aug 19, 2026
Trading halt
Trading Halt: CURX — T1 (News Pending)
Curanex Pharmaceuticals Inc CS | Market: NASDAQ | Code: T1 — News Pending
Aug 19, 2026
Trading halt
Trading Halt: CURX — T3 (News and Resumption Times)
Curanex Pharmaceuticals Inc CS | Market: NASDAQ | Code: T3 — News and Resumption Times
May 14, 2026
Earnings
Curanex Reports First Quarter 2026 Business Progress as Phyto-N Advances Toward Planned FDA Submission
Completed GMP manufacturing and toxicology milestones supporting planned Q4 2026 IND submission for ulcerative colitis

Short side

FINRA· Oct 15, 2026
🔒 Subscribers only
shares short
Trading halts
Aug 19, 2026Resumption ScheduledResumed
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 19, 2026 SEC
Curanex Pharmaceuticals disclosed two newly filed securities class actions related to its August 2025 IPO. Both…
8-K — Impact 4/10
Sep 3, 2026 Listing status
Listing Status: CURX — Normal (was Deficient)
Curanex Pharmaceuticals Inc - Common Stock | Nasdaq Financial Status Indicator D → N
Aug 17, 2026 SEC
Curanex Pharmaceuticals filed a Certificate of Amendment with the Nevada Secretary of State to effect a 1-for-20…
8-K — Impact 3/10
Jun 30, 2026 Inst.
CITADEL ADVISORS LLC — ADD
95,258 shares ($25.3K)
Jun 30, 2026 Inst.
GEODE CAPITAL MANAGEMENT, LLC — TRIM
38,288 shares ($10.2K)
May 14, 2026 SEC
Curanex Pharmaceuticals provided a Q1 2026 business update highlighting preclinical progress with lead candidate…
8-K — Impact 3/10
Mar 30, 2026 Press
Curanex Pharmaceuticals issued a press release highlighting operational progress in advancing its lead asset, Phyto-N…
Impact 3/10

SecBot reports

6 filings · 1 press release · 0 bullish · 0 bearish · 6 neutral
All CURX filing & press-release reports (7)